002872 ST天圣制药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-1.847-4.267-4.355-4.065-2.939
总资产报酬率 ROA (%)-1.361-3.151-3.220-2.974-2.004
投入资产回报率 ROIC (%)-1.524-3.574-3.701-3.376-2.320

边际利润分析
销售毛利率 (%)48.89647.65247.08356.57441.264
营业利润率 (%)-16.681-16.505-16.152-13.955-8.279
息税前利润/营业总收入 (%)-15.052-16.092-15.196-12.495-6.170
净利润/营业总收入 (%)-15.898-15.472-16.176-15.083-9.820

收益指标分析
经营活动净收益/利润总额(%)120.17373.922101.621125.389141.257
价值变动净收益/利润总额(%)-0.180-16.938-2.123-5.850-8.395
营业外收支净额/利润总额(%)-0.3133.8431.214-0.701-12.026

偿债能力分析
流动比率 (X)2.0981.9551.5201.4691.947
速动比率 (X)1.7691.6581.2211.2341.684
资产负债率 (%)25.63226.38025.44526.36026.948
带息债务/全部投入资本 (%)11.75310.4736.8267.15511.136
股东权益/带息债务 (%)700.976788.7911,244.1261,188.356729.639
股东权益/负债合计 (%)288.899277.872292.414278.749270.393
利息保障倍数 (X)-9.547-15.000-13.169-9.164-5.053

营运能力分析
应收账款周转天数 (天)80.34284.23590.60092.643182.129
存货周转天数 (天)160.581146.673156.822174.443171.872